The drug industry maintains that policies like foreign reference pricing and letting Medicare negotiate prices would harm innovation. But closer examination reveals that while there is truth to that claim, it's more complex than it appears at first glance.
The announcement came as the candidate announced his own healthcare policy proposals, which seeks to build on existing provisions in the Affordable Care Act, while opening up a new public option for coverage.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.